The disclosure relates to the field of molecular biology, and in particular relates to the use of CXCL 14. According to the present invention, different antigen proteins are transferred to the surface of a DC cell by means of the chemotactic binding capacity of CXCL 14 and surface receptors of immune cells such as DC cells. A chemokine of CXCL14 can effectively induce the binding of an antigen molecule to a specific immune cell at the N-terminal of an antigen protein, such that the cross presentation effect of the antigen molecule is greatly enhanced, and CXCL14 can finally induce a stronger specific immune response of the antigen molecule.

The present invention relates to vectors, such as DNA plasmids, comprising multiple nucleic acid sequences engineered to be co-expressed as separate molecules. Such separate molecules include a first polypeptide, wherein the first polypeptide comprises a targeting unit that targets antigen-presenting cells, a multimerization unit, such as dimerization unit, and an antigenic unit comprising one or more antigens or parts thereof, and one or more immunostimulatory compounds.

A use of CCL26. Different antigen proteins are delivered to the surfaces of DC cells by utilizing a chemotactic binding capacity of CCL26 to surface receptors of immune cells such as the DC cells, so that the efficiency of phagocytosis, processing and presentation of different antigen proteins by the DC cells is improved, and the effect of preventing and treating related diseases is improved by further adding a T2 sequence into an antigen. The T2 sequence has a very strong immunological enhancement effect by means of experimental determination, and can further excite body fluid and cellular immune response in the process of promoting antigen presentation, thereby finally achieving the effect of inhibiting related tumor growth.

The present disclosure relates to CCL22 as a T cell target in cancer immunosuppression.

The present disclosure relates to CCL22 as a T cell target in cancer immunosuppression.